TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Taysha Gene Therapies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-1130.6%
Net margin
-1115.3%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.3% | +57.5% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -47.8% | -68.5% | |
| Return on assets | – | -46.4% | -43.3% | |
| Current ratio | 0.10 | 36.17 | 12.23 | |
| Debt to equity | – | – | 0.20 | |
| Interest coverage | – | -1535.8× | -1753.9× | |
| Capex to revenue | – | – | 7.6% | |
| Diluted shares | – | 18M | 320M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Taysha Gene Therapies generated $452.77M from operations and spent $40.90M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$452.77M
Used
$40.90M
Capital expenditure$40.90M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1115.3%
×Asset turnover0.04×
×Equity multiplier1.58×
=Return on equity, FY2025-68.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1115.3% | 0.04× | 1.58× | -68.5% |
| FY2024 | -1071.6% | 0.05× | 2.27× | -121.9% |
| FY2023 | -722.1% | 0.10× | 3.94× | -294.0% |
| FY2022 | -6635.3% | 0.01× | 3.53× | -344.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$109.00M
- Cash generatingOperating cash flow above zero-$93.09M
- Return on assets improvedROA up on the prior year-51.7% → -68.0%
- Earnings backed by cashOperating cash flow above net income-$93.09M vs -$109.00M
- Less leverageLong-term debt to assets fell27.4% → 14.6%
- Better liquidityCurrent ratio rose5.42 → 12.23
- No dilutionShare count did not rise250M → 320M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.05 → 0.06